The COVID-19 pandemic exposed critical vulnerabilities in the global IVD supply chain — from shortages of reagent-grade chemicals and membrane materials to bottlenecks in swab and tube production — that disrupted test availability at precisely the moment demand was highest. The industry has been rebuilding supply chain resilience ever since, but the concentration of raw material manufacturing in China and a small number of specialty chemical suppliers remains a strategic vulnerability. Nitrocellulose membranes for lateral flow tests, monoclonal antibodies, enzymes for molecular assays, and specialty plastics for consumables each have concentrated supply chains that can fail under demand shock. The CHIPS Act parallel in diagnostics — investment in domestic reagent manufacturing capacity — is beginning to emerge as a policy priority in the U.S. and EU.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• IVD Supply Chain Overview — Raw Materials, Components, and Manufacturing Structure
• Nitrocellulose and Membrane Materials — Supply Concentration and Resilience Investment
• Monoclonal Antibodies and Biological Reagents — Manufacturing, Quality, and Supply Strategy
• Enzymes and Molecular Biology Reagents — PCR, NGS, and Isothermal Amplification Supply
• Specialty Plastics and Consumables — Tubes, Swabs, Cards, and Microfluidic Substrates
• Contract Manufacturing — CMO/CDMO Landscape for IVD Reagents and Components
• Post-COVID Lessons — Inventory Strategy, Dual Sourcing, and Emergency Procurement
• Geopolitical Supply Risk — China Dependence, Reshoring, and Near-Shoring Strategies
• Regulatory Requirements — Supply Chain Documentation, IVDR Traceability, and FDA QSR
• Investment and Partnership Opportunities — Supply Chain Technology and Resilience Infrastructure
Table of Contents
1. Executive Summary
2. Market Overview
3. IVD Supply Chain Overview
4. Nitrocellulose and Membrane Materials
5. Monoclonal Antibodies and Biological Reagents
6. Enzymes and Molecular Biology Reagents
7. Specialty Plastics and Consumables
8. Contract Manufacturing
9. Post-COVID Lessons
10. Geopolitical Supply Risk
11. Regulatory Requirements
12. Competitive Landscape
13. Regional Market Analysis
14. Strategic Conclusions and Recommendations
15. Appendix
List of Tables
Table 1. IVD Raw Material Supply Chain — Concentration Risk Assessment by Category
Table 2. Nitrocellulose and Membrane Materials — Supplier Landscape and Risk Assessment
Table 3. Monoclonal Antibodies — Supplier Landscape and Manufacturing Capacity
Table 4. Enzymes and Molecular Biology Reagents — Supplier Landscape and Risk Assessment
Table 5. CMO and CDMO Landscape — IVD Reagent and Component Manufacturing 2025
Table 6. Geopolitical Supply Risk — China Dependence by Raw Material Category
Table 7. Reshoring and Near-Shoring Investment — Leading IVD Supplier Programs 2025
Table 8. IVDR and FDA QSR — Supply Chain Compliance Requirements
Table 9. Digital Supply Chain Platforms — Leading Solutions and Adoption Status
Table 10. Key Risks and Mitigation Strategies
Companies Profiled
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Bio-Rad Laboratories
Becton Dickinson
bioMérieux
Hologic
Qiagen
DiaSorin
Sysmex
